J&J: new positive data for Tremfya
(CercleFinance.com) - J&J reports that Janssen Pharmaceuticals (a Johnson & Johnson company) today presented new data from a Phase 3 study demonstrating the efficacy and safety profile of Tremfya (guselkumab) in patients with active ulcerative colitis (UC) for up to 24 weeks.
High rates of clinical response were observed at weeks 12 or 24, with no new safety signals observed in relation to the safety profile of Tremfya in its approved indications.
Ulcerative colitis is a complex immune-mediated disease that can cause a wide range of often debilitating symptoms, a related source said, adding that these results support Tremfya's potential as a durable, fast-acting treatment option.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
High rates of clinical response were observed at weeks 12 or 24, with no new safety signals observed in relation to the safety profile of Tremfya in its approved indications.
Ulcerative colitis is a complex immune-mediated disease that can cause a wide range of often debilitating symptoms, a related source said, adding that these results support Tremfya's potential as a durable, fast-acting treatment option.
Copyright (c) 2023 CercleFinance.com. All rights reserved.